Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Red Star Research LLC

Neither a doctor nor a teaching hospital

Research payments

$753,178

184 payments

Through program year 2025, Red Star Research LLC is reported as receiving $753,178 in research payments, across 184 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $66,056 70
2024 Research $92,062 37
2023 Research $95,782 21
2022 Research $124,441 23
2021 Research $352,884 31
2020 Research $21,954 2

Breakdown

Who paid Research payments · program years 2020–2025
  1. Biohaven Pharmaceuticals, Inc. $374,838 33 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $187,941 71 payments
  3. Pfizer Inc. $137,068 69 payments
  4. AbbVie, Inc. $53,331 11 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $229,355 19 payments
  2. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $157,731 14 payments
  3. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $120,599 9 payments
  4. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $49,663 9 payments
  5. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $46,339 9 payments
  6. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With A History of Inadequate Response to Oral Preventive Medications $31,561 37 payments
  7. A Phase 4 Randomized Doubleblind Placebocontrolled Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use $30,718 67 payments
  8. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $23,799 6 payments
  9. A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $16,284 1 payment
  10. A Phase 3 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents 6 to 18 Years of Age $16,190 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record